Industry Literature

The OCS Heart EXPAND Trial is a prospective, multi-center trial to evaluate the effectiveness of the OCS™ to resuscitate, preserve and assess donor hearts that may not meet current standard donor heart criteria for transplantation to potentially improve donor heart utilization for transplantation.

At present the assessment of the heart transplant (HTx) recipient’s personal alloimmune risk is still not precise enough. The aim of this study was to evaluate the impact of molecular-level human leukocyte antigen (HLA) matching on post-transplant graft survival, rejection and cardiac allograft vasculopathy (CAV).

To describe technical aspects of angiography and intravascular ultrasound (IVUS) in ex-vivo perfused hearts using the Organ Care System (OCS, TransMedics, Andover, MA USA).

The new French allocation system (NFAS) based on the candidate risk score has been launched on January 2, 2018. This study aimed to evaluate the effect of implementation of NFAS on newly registered candidates’ profile and their waitlist outcomes.

The lack of donor organs limits the availability of heart transplantation as an optimal treatment option for advanced heart failure patients. In an effort to expand a pool of acceptable donor organs we explored a correlation between donor age and 1-year outcome in patients undergoing heart transplantation.

Risk stratification and early detection of cardiac allograft vasculopathy (CAV) are essential in heart transplantation patients. CAV presents a diffuse vascular involvement, and has been difficult to noninvasively diagnose by the lack of a sensitive method to detect developing vascular pathology in the allograft. The present study investigates the ability of 13N-ammonia PET for detection

In the United States, heart allocation is administered by the United Network for Organ Sharing (UNOS). UNOS collects demographics and clinical data for all transplant candidates, donors, and recipients listed since 1995. While the data is available to the public upon requests; it has been used predominately for research rather than clinical decision making, transplant

Among patients who undergo orthotopic heart transplant (OHT), intravascular ultrasound (IVUS) detection of coronary allograft vasculopathy (CAV), defined as ≥ 0.5 mm increase in maximal intimal thickness (Δ MIT), is associated with worse outcomes at 5 years. Other IVUS-derived measurements of arterial plaque, while validated in studies of coronary atherosclerosis, have not been well studied

Despite the controversial effect of elevated heart rate on progression of cardiac allograft vasculopathy (CAV), heart-rate-slowing agents are frequently prescribed with the assumption that higher heart rate predicts worse outcomes in cardiovascular disease.

Psychosocial assessment is a key component of heart transplantation (HT) evaluation. Criteria such as patient compliance to medical therapy, level of social support, and history of substance abuse are important considerations when assessing appropriateness for listing. The aim of this study was to characterize the patients who do not satisfy listing criteria due to psychosocial